High Volume Subcutaneous Drug Delivery
|出版商||Greystone Research Associates||商品編碼||358327|
The trend favoring biological drugs as a percent of all drugs continues to accelerate. Most are injectables and many require volumes that exceed 1 mL per dose, the de facto limit for comfortable and safe patient self-administration. As result, the majority of biologicals are supplied for delivery via infusion. The demographics of patient populations and the current trend in therapeutic drug development are converging to create an increasingly steep demand curve for infusion. The costs and logistics of this convergence are a major driver of the efforts to develop and commercialize high volume drug delivery products that can be administered subcutaneously. We expect the number of therapeutic drugs in this class to grow significantly by the end of the decade, creating significant opportunities for high volume subcutaneous drug delivery products.